Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation
in the past two decades as a promising molecular target for prostate cancer (PCa). Its …

At present, prostate cancer remains the second most occurring cancer in men, in Europe.
Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration …

The aim of the review was to evaluate patient and treatment characteristics for patients with
metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand …

Simple Summary Radioligand therapy (RLT) targeting prostate-specific membrane antigen
(PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate …

Introduction A new therapeutic option for metastatic castration–resistant prostate cancer
(mCRPC) of heavily pre-treated patients lies in 177 Lu-PSMA-617 radioligand therapy …

Theranostics, a combination of therapy and diagnostics, is a field of personalized medicine
involving the use of the same or similar radiopharmaceutical agents for the diagnosis and …

Abstract Purpose of Review To critically review the potential clinical applications of prostate-
specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC) …

To date, several papers have been published about prostate-specific membrane antigen
(PSMA)-based radioligand diagnostic and therapeutic approaches. This paper mainly …

In light of widely expanding personalized medicine applications and their impact on clinical
outcomes, it is naturally befitting to explore all the dimensional aspects of personalized …

Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) based
radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine …